Compare EXPI & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | VERA |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | EXPI | VERA |
|---|---|---|
| Price | $10.58 | $49.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $12.00 | ★ $67.67 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,678,653,000.00 | N/A |
| Revenue This Year | $6.03 | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $6.90 | $18.53 |
| 52 Week High | $13.35 | $50.16 |
| Indicator | EXPI | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 83.43 |
| Support Level | $10.16 | $40.38 |
| Resistance Level | $10.71 | $47.10 |
| Average True Range (ATR) | 0.38 | 3.35 |
| MACD | -0.08 | 1.34 |
| Stochastic Oscillator | 22.06 | 99.33 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.